ABVC BioPharma

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clinical Trials Continue Despite COVID-19 Restrictions

ABVC BioPharma Reports Second Quarter 2021 Results

JERSEY CITY, N.J., Aug. 6, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of an underwritten public offering of 1,100,000 units for ABVC BioPharma, Inc. (NASDAQ: Common stock – ABVC) at an offering price of $6.25 per unit for total gross proceeds of $6.875 million, before deducting underwriting discounts and commissions and other estimated offering expenses and before any exercise of the underwriters' overallotment option.

WallachBeth Capital Announces the Completion of an Underwritten Public Offering of 1,100,000 Units for ABVC BioPharma, Inc.

FREMONT, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced the pricing of its firm commitment offering of 1,100,000 Units at an offering price of $6.25 per unit for total gross proceeds of $6.875 million.

ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering

American BriVision holds key differentiators via novel botanical treatment solutions in key end markets. 2 of the company's candidates have the potential to fulfil a wide treatment void.

American BriVision: Deep Dive Into Market Potential

via NewMediaWire  -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, yesterday issued a letter to its more than 700 shareholders describing the company's achievements in 2020 and goals for 2021. The letter from Dr. Howard Doong, CEO of ABVC, is reprinted below in its entirety.

American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021

News for ABVC BioPharma Stock (ABVC)